BPC-157 — reference

BPC-157: synthetic pentadecapeptide (research use only), approximate mass 1419.5 Da, Short; not well characterised in humans half-life. Identity, evidence base, analytical considerations and limitations.

Scope

A maintained identity and evidence reference for BPC-157. It is deliberately narrow: what the molecule is, what has been published about it, and what an analytical report on it can and cannot establish. It contains no dosing recommendations and is not advice about anyone's care.

Where a figure is approximate this page says so. Where something is unknown, it says that instead of filling the gap.

Identity

Masses quoted here are approximate and are given for orientation when reading an analytical report. For a mass-error calculation, use the exact monoisotopic mass computed from the elemental composition rather than a rounded figure from a reference page, including this one.

What it is

BPC-157 is a 15-residue sequence derived from a fragment of human gastric juice protein BPC. The preclinical literature is extensive, largely from a small number of research groups, and reports effects across a very wide range of injury models.

The breadth of reported effects is itself worth noting. A compound that improves outcomes in tendon, muscle, gut, nerve and bone models through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

Evidence base

Published studies and programmes most relevant to this compound:

• No adequately powered, published, randomised controlled human trials known to us

The absence of adequately powered published randomised human trials is the central fact about this compound and no amount of mechanistic plausibility substitutes for it. This site states that plainly rather than hedging.

Analytically it is a simple target: a short sequence with an unambiguous mass, straightforward to confirm by LC-MS and to assay by reversed-phase HPLC. Identity confirmation is easy; that is not the same as knowing what it does.

Individual digests for several of these are maintained separately in this commons and are linked from the evidence category. A digest is a summary with its criticisms attached; it is not a substitute for reading the paper.

Analytical considerations

Reversed-phase HPLC with ultraviolet detection at 214 nm is the usual purity method, and electrospray mass spectrometry the usual identity method. A purity figure is an area percentage at a stated wavelength under a stated gradient, and it is not interchangeable with a content determination.

Three things a purity assay on this compound will not tell you: how much peptide is in the container (that requires a content assay), what the counter-ion is (that requires ion chromatography or NMR), and whether anything is present that does not elute under the method used.

See Reversed-phase HPLC for peptides and LC-MS identity confirmation for the method detail.

Status and legality

Research use only. Not approved for human use in any jurisdiction we are aware of.

Material sold as research-use-only is not a licensed medicine, whatever it contains and however good its certificate is. That is a statement about regulatory status rather than about quality, and it is true of high-purity material as much as of poor material.

Limitations of this page

This is a reference page maintained by volunteers, reviewed on the date shown, and it will be out of date at some point after that date. It summarises published work rather than reproducing it, and a summary always loses something. Where the summary and the source disagree, the source is right.

If you find an error, the fastest route to fixing it is a topic in doc review naming the sentence and the source. The maintainers named above are notified.